Project Grant R21AG103462
Award Date 8/15/26
Completion Date 7/31/28
Dollars Obligated $428K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- The National Institute on Aging awarded The Trustees of Columbia University in the City of New York $452,375 on January 1, 2026, under the Aging Research program (CFDA 93.866) to investigate astrocyte-mediated tonic inhibition in a mouse model of Lewy body dementia. The research explores mechanisms linking GBA1 gene mutations to Lewy body dementia pathology by using an astrocyte-specific GBA1 conditional knockout mouse model crossed with a THY1-ASYN transgenic model that overexpresses human...
- This $2,069,215 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research by Case Western Reserve University to investigate the role of the beta-arrestin2-LMBRD2 pathway in the transmission and toxicity of pathological alpha-synuclein, which is a defining hallmark of Lewy body diseases such as Parkinson's disease and dementia with Lewy bodies. The research will utilize cellular and animal models to study the mechanisms by which beta-arrestin2...
- The National Institute of Neurological Disorders and Stroke awarded The Washington University $163,079 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to conduct research on cerebrospinal fluid and skin biomarkers of cognitive decline in Parkinson disease and Lewy body dementia. The research validates candidate synaptic protein biomarkers (neuronal pentraxin 2 and somatostatin) in cerebrospinal fluid that may...
- The National Institute on Aging awarded The Washington University $642,991 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate genetic drivers of phenotypic variability in autosomal dominant Alzheimer's disease using a multi-omics approach. The research identifies genetic alterations associated with Alzheimer's disease risk and presentation in individuals carrying mutations in the PSEN1, APP, and PSEN2 genes. The project characterizes transcriptomic brain profiles...
- The National Institute on Aging awarded The Washington University $651,035 on August 15, 2026, under the Aging Research program (CFDA 93.866) to develop predictive markers for amyloid-related imaging abnormalities in Alzheimer's disease patients treated with amyloid-targeted therapies. The project integrates data from two complementary cohorts: the Dominantly Inherited Alzheimer Network Trials Unit, the longest-treated anti-amyloid cohort with harmonized clinical, imaging, and biomarker data and...
- The National Institute on Aging awarded The Washington University $246,225 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop an ultrasensitive, multiplexed plasmonic-fluor-linked immunosorbent assay (P-FLISA) for quantitative measurement of plasma phosphorylated tau 217 (P-TAU217), amyloid-beta 42 (AB42), and amyloid-beta 40 (AB40) as neurological biomarkers for early Alzheimer's disease detection. The project will deliver two specific research aims. Aim 1...
- The National Institute on Aging awarded $427,625 to The Washington University on September 1, 2026, under the Aging Research program (CFDA 93.866) to probe cerebellar cortex computations in Alzheimer's disease. The work examines cerebellar nodulus and uvula function in two Alzheimer's disease mouse models—APP/PS1 and 3XTG-AD—at 3, 6, and 12 months of disease progression to assess how hallmarks of Alzheimer's disease contribute to cerebellar dysfunction. The project tests the hypothesis that...
- The National Institute on Aging awarded The Washington University $150,114 on March 18, 2026, under the Aging Research program (CFDA 93.866) to investigate the role of brain-engrafted monocyte-derived macrophages in Alzheimer's disease. The research examines how monocyte-derived macrophages infiltrating the brain contribute to Alzheimer's disease pathology. The F99 phase involves assessing the effects of promoting or depleting brain-engrafted monocyte-derived macrophages on amyloid plaque...
- The National Institute on Aging awarded The Washington University $129,876 under the Aging Research program (CFDA 93.866) on June 15, 2026, to investigate the relationship between tau accumulation, white matter degeneration, and cognition in preclinical Alzheimer disease. The funded research uses autosomal dominant Alzheimer disease (ADAD) cohorts enrolled in the Dominantly Inherited Alzheimer Network (DIAN) to examine how tau tangle accumulation and white matter microstructural damage precede...
- This $427,625 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to elucidate the mechanisms by which microgliopathy, a genetic neurological disorder, causes early-onset dementia. The research will investigate how the loss of the DAP12 protein in microglia, the immune cells of the brain, leads to heightened signaling of the RUNX and STAT3 pathways. This dysregulation is hypothesized to disrupt normal microglial functions and induce brain pathology and...